The Fox Chase Cancer Center in Philadelphia has formed a groundbreaking partnership with Arima Genomics, Inc. from Carlsbad, California, aimed at revolutionizing cancer diagnostics through the use of advanced three-dimensional (3D) DNA analysis. This collaboration marks a significant shift in cancer care, moving beyond conventional genetic testing by focusing on the structural organization of DNA within cells, which researchers believe can illuminate critical genomic changes often overlooked by standard sequencing methods.
Innovative Approach to Cancer Diagnostics
At the heart of this initiative is the Cancer Epigenetics Institute at Fox Chase, which will integrate Arima’s unique Hi-C technology into its diagnostic processes for conditions such as lymphoma and sarcoma. By utilizing Arima’s Aventa Lymphoma and Aventa FusionPlus tests, the institute aims to detect complex gene fusions and rearrangements that contribute to cancer development and progression.
Johnathan Whetstine, director of the Cancer Epigenetics Institute, emphasized the importance of this partnership, stating, “This partnership represents a true bench-to-bedside translation of discovery.” He noted that the collaboration has evolved from years of foundational research into practical clinical applications, redefining how genomic organization can impact diagnosis and treatment strategies.
Unlike traditional DNA sequencing that fragments genetic material, Arima’s technology preserves the spatial context of the genome. This comprehensive perspective is expected to provide deeper insights into tumor formation, evolution, and resistance to treatment.
Transforming Cancer Care
According to peer-reviewed studies and clinical applications across various institutions, Arima’s Aventa tests have shown remarkable efficacy in identifying gene fusions and rearrangements crucial for accurate diagnoses, particularly in lymphomas and sarcomas. Tom Willis, chief executive officer of Arima Genomics, expressed enthusiasm for the partnership, declaring it a pivotal step in transforming cancer care. “Arima’s Aventa tests provide the most sensitive detection for gene fusions and rearrangements,” he stated.
This collaboration positions Fox Chase as the first institution globally to implement Arima’s 3D genomics testing as a standardized protocol across diverse tumor types. The integration will also include the collection of de-identified patient response data, which will help researchers identify patterns and potential therapeutic avenues.
Whetstine remarked that this innovative technology will allow clinicians to not only observe genetic changes but also understand how DNA is organized, potentially unveiling new therapeutic targets with increased precision. “It allows us to see not just what genetic changes occur, but how the DNA itself is organized,” he said.
The technology could be particularly beneficial for challenging blood cancers. Peter Abdelmessieh, an assistant professor at Fox Chase’s Blood Cancer and Cellular Therapy Institute, highlighted the significance of this partnership, noting that although advancements have been made in treating lymphoma, the disease frequently relapses. Access to Arima’s advanced tools could be instrumental in guiding diagnosis and treatment decisions for these patients.
This partnership builds upon a long-standing scientific relationship between Arima and the Cancer Epigenetics Institute, reflecting years of joint research efforts and collaborative participation in symposia. Both organizations view this collaboration as a new frontier for cancer diagnostics, paving the way for enhanced patient outcomes.
